CS Paper Radar

Unlocking the Regulatory Genome by ARGUS: An Evidence-Constrained Agentic Framework for Interpreting Single Nucleotide Variants

Pratik Dutta, Matthew B. Obusan, Max Chao, Rekha Sathian, Nimisha Papineni, Ramana V. Davuluri

cs.AI q-bio.GNcs.LG ·submitted 2026-10-08 16:38 UTC · v1
publishedcode/data

Abstract

Over 90% of disease-associated variants from genome-wide association studies fall in noncoding regulatory regions, yet their functional interpretation remains a central open problem in genomic medicine. Large language models prompted to interpret such variants routinely hallucinate transcription factor (TF) binding changes, fabricate experimental support, and assign biological significance to statistically negligible signals. We present ARGUS (Agentic Regulatory Genomics for an Uncertainty-aware Scientist), which strictly separates deterministic biological computation from LLM-mediated reasoning. ARGUS wraps 458 DNABERT-based TF binding models in a hypothesis-directed investigation loop where a planner selects evidence sources based on current uncertainty, a verifier deterministically interprets each observation, and intermediate results change the investigation path. On variant rs6983267 at the 8q24 cancer risk locus, the same planner produces four divergent trajectories for four TFs. FOXA1 is rescued in 3 steps when real ADASTRA allele-specific binding data (15 experiments, FDR = 0.030) reveals a model false negative masked by saturation. KLF6 traverses 8 steps across ADASTRA, JASPAR motif analysis, and ENCODE cCRE regulatory annotation before abstaining due to mixed indirect evidence. RAD21 abstains in 8 steps after ADASTRA returns a coverage-qualified but nonsignificant allelic test (5 experiments, FDR = 0.65), and SP1, which shares FOXA1's saturated retained prediction, abstains because no direct experimental evidence exists at this locus. All observations come from real ADASTRA, JASPAR, and ENCODE cCRE queries; none are simulated. A comparison of fixed-priority and LLM-mediated planning shows that the LLM planner reaches identical verdicts with fewer tool calls by declining evidence that cannot resolve the claim under test.

Comment
Accepted at the NeurIPS 2026 Workshop on Agentic AI for Biological Discovery (AgenticLS). Code: https://github.com/duttaprat/ARGUS

Closest papers

Nearest neighbours by meaning across the whole index.

Orchestra: Corroboration-Based Regulatory Candidate Discovery via Composed Bioinformatics MCP Agents

cs.MA q-bio.MN ·2026-08-27 ·Jose A. Bird
similarity 0.62
Abstract · 20 pages, 3 figures. v4: driver reference set changed from OncoKB to IntOGen; data re-collected on RegNetAgents v1.3.0 / CASCADE v1.5.0 with…

Orchestra composes two independently built bioinformatics MCP servers -- RegNetAgents, which infers regulatory network topology, and CASCADE, which provides independent functional evidence (LINCS knockdown, DepMap essentiality, super-enhancer status, DoRothEA transcription-factor confidence) -- into one multi-agent LangGraph workflow. Its central claim is that requiring the two systems to agree on a candidate regulator yields a more trustworthy candidate than either alone. We test this on the TCGA tumor-acquired regulator tier, selecting each query's ten regulators by ARACNe mutual-information edge weight. Across BRCA/COAD focal genes and matched negative controls, requiring at least 2 of 4 evidence sources predicts known-driver status (IntOGen) among focal genes (odds ratio 3.15, Benjamini-Hochberg-adjusted p=0.016; 2.92 after deduplication) but shows no association among negative controls (p=0.70); a single source does not in BRCA/COAD. In a second panel (STAD) the pattern reproduces and is stronger (OR 6.71, adjusted p=0.0047), again with no association in controls. Corroboration adds value beyond MI edge weight in both panels (BRCA/COAD p=0.039; STAD p=0.0001), though modestly in BRCA/COAD. Deduplication, a permutation test and a reproduction of RegNetAgents' published results agree; a second, separately derived driver list (Vogelstein et al. 2013) is directionally consistent but too sparse to reach significance. All experiments invoke Orchestra's real agentic entry point.

0.35

LLM sequential decision making under uncertainty in biochemical domains

cs.AI ·2026-09-27 ·Mattias Akke, Soojung Yang, Jurgis Ruža, Sathya Edamadaka, Rafael Gómez-Bombarelli
benchmark similarity 0.62
Abstract

Large language models (LLMs) are increasingly used to drive scientific discovery. Understanding how LLMs make decisions from new data and memory of the literature is vital before trusting them to design experiments under tight experimental budgets. However, their decision strategies are invisible in the current performance scores used to evaluate research agents. Here, we benchmark five frontier LLMs in a Bayesian Optimization setting against published statistical baselines on seven combinatorial datasets spanning protein engineering, reaction optimization, molecular design, peptide self-assembly, and catalysis. Performance is paired with direct measurements of model beliefs and actions, enabling highly resolved behavior analysis. A prompt ablation that progressively strips context separates memorization from chemical reasoning and from bare categorical optimization. Prior chemical knowledge helps in expectation, but with high variance and occasionally even harms performance. No configuration tested decisively beats a mean statistical baseline across domains. Belief-movement and Martingale diagnostics, corrected here for a measurement-noise bias that mislabels rational agents as irrational, show that models overreact to incoming data rather than entrenching on their priors in the contexts studied here. Interestingly, while LLM actions are exploitative, models sincerely intend to explore and consistently act on that intent. This failure is a competence gap arising from context-stickiness. Removing in-context history restores exploration, indicating that priors and data must be decoupled to achieve effective LLM-driven discovery.

0.07

Do Language Models Know What Compelling Scientific Evidence Looks Like?

cs.LG cs.AIcs.CL ·2026-10-29 ·Conor Igoe, Gabriel Grand, Zane Koch, Albert Bou, Eli Moss +4 more
benchmark similarity 0.62
Abstract

Expert scientists excel at weighing empirical findings from multiple sources that vary in both statistical reliability and epistemic relevance. To what extent are language models, which are increasingly driving autonomous discovery systems, capable of such evidence deliberation? We introduce EDB-Bio, a scientific reasoning benchmark curated from real-world data in three biological domains: drug-perturbation transcriptomics, CRISPR screens, and human genome-wide association studies (GWAS). Each of EDB-Bio's 96k episodes presents a sequence of experimental results from published studies and asks the model to predict the probability that a target hypothesis is true. Out-of-the-box, open-weight and frontier models alike demonstrate systematic underconfidence and attain Brier scores comparable to a trivial base-rate forecaster. Post-training against strictly proper scoring rules significantly improves both calibration and discrimination. This calibration pays off downstream: in a sequential experiment selection task, our Ibis0 model is 2.5 times more efficient than the best frontier model. Throughout, quantifying evidence weights as Bayes factors reveals how models update their beliefs over time, whether they agree with expert biologists on relevance, and where they exhibit inconsistencies and biases. Our work extends calibration training and uncertainty analysis to a realistic scientific forecasting setting with applications to human cancer biology. We release all code, data, and trained models.

0.20

AVA: Agentic Variant Adjudication for Automated, Auditable Read-Level Review in Cancer Diagnostic Sequencing

cs.AI q-bio.GN ·2026-11-05 ·Caleb Chin, Sidharth Gupta, Arun K Anguraj Vadivel, Robert Siddaway, Siddharth Arya +3 more
publishedbenchmark similarity 0.60
Abstract · 14 pages, 5 figures. Accepted at ML4H (Machine Learning for Health) 2026 Findings Track

Identifying a tumor's DNA mutations is central to cancer diagnosis and treatment, but distinguishing genuine mutations from sequencing artifacts is error-prone. In practice, genuine mutations are identified using fixed variant-allele-frequency (VAF) and depth thresholds which cannot separate artifacts from genuine mutations in the borderline low-VAF zone where they overlap. A laboratory specialist must manually inspect the read-level sequencing data, a slow step that has high inter-rater variability and causes diagnosis delays. We present AVA: Agentic Variant Adjudication; an agentic framework that automates this read-level inspection with subagents that reason over evidence, generate investigative code, and return a real-or-artifact adjudications with an auditable reasoning trace all without training on existing data. On both the SEQC2 DNA-seq benchmark and patient RNA-seq data, restricted to a subsample of borderline variants where thresholds fail, both closed-source (Claude Sonnet 5) and open-weight (GLM 5.3 Flash and Gemma 4 31b) agents outperform the best achievable VAF/depth thresholds. Ultimately, AVA is suited for privacy-constrained clinical deployment, since the framework can run on locally deployed open-weight models with descriptive reasoning traces to keep specialists in the loop.

0.27

GenoMorph: Pathway-Grounded Genomic Disease Reasoning via Adaptive Latent Computation

cs.AI q-bio.GN ·2026-09-28 ·Tanmoy Kanti Halder, Akash Ghosh, Arijit Roy, Sriparna Saha
benchmark similarity 0.60
Abstract

Large language models (LLMs) have demonstrated strong capabilities in biological reasoning; however, genomic disease inference remains largely dependent on memorized gene-disease associations rather than understanding biological pathways. This shortcut learning undermines robustness and generalization, and breaks down when molecular identifiers are unavailable. We present GenoMorph, a multimodal genomic reasoning framework that shifts disease prediction from associative gene-disease mapping toward pathway-grounded reasoning. GenoMorph couples a frozen DNA foundation model with question-conditioned cross-attention fusion, self-adaptive latent reasoning (LatentSp), a residual reasoning gate for iterative genomic evidence reinjection, and rejection sampling fine-tuning regularized by hierarchical optimal transport (OT). Rather than learning direct gene-disease mappings, GenoMorph aligns genomic sequence representations with latent pathway dynamics, enabling reasoning trajectories that follow molecular interactions before producing disease predictions. LatentSp dynamically allocates computation according to reasoning confidence, reducing unnecessary reasoning steps and improving inference efficiency. We further construct an anonymized benchmark from the Kyoto Encyclopedia of Genes and Genomes (KEGG), replacing every gene and molecular identifier with anonymous symbols while preserving sequences and pathway topology, thereby removing memorization shortcuts. GenoMorph raises the weighted F1 from 0.7863 (BioReason) to 0.9412, and rejection sampling fine-tuning with self-adaptive latent reasoning pushes it to 0.9725 while cutting latency nearly 60%. On the anonymized benchmark it reaches 0.9465 F1, substantially outperforming prior systems and confirming that accurate disease prediction can arise from pathway reasoning rather than memorized gene-disease associations.

0.20

Conformal Prediction for Molecular Properties under Label Shift

cs.LG ·2026-08-18 ·Hyeonsu Lee, Juyeon Kim, Erkhembayar Jadamba, Seungjin Choi, Hyunjin Shin
published similarity 0.59
Abstract · NeurIPS 2025 Workshop on Reliable ML from Unreliable Data

Drug discovery and development underpins healthcare but remains costly and failure-prone. A critical bottleneck lies in predicting molecular properties such as solubility, potency, and toxicity, which directly determine whether a candidate can advance from preclinical to clinical trials. Artificial Intelligence (AI) has accelerated this process, yet its reliability is often undermined by distribution shift, as experimental conditions frequently diverge from training data. In addition, conventional point predictions provide only single-value estimates, offering limited guidance for high-stakes experimental design. We address these challenges with a conformal prediction framework tailored to label shift. By weighting conformal scores using marginal label probability ratios, our method produces statistically rigorous prediction intervals without retraining. This enables robust uncertainty quantification even when property distributions drift, directly tackling one of the most pervasive obstacles to applying AI in real-world drug development. By moving beyond accuracy alone to provide actionable confidence measures, our approach enhances the trustworthiness of AI-driven predictions. This further aligns predictive modeling with regulatory demands for transparency and uncertainty reporting and ultimately supports more reliable decision-making in billion-dollar development pipelines.

0.43

Auditing Tool Traces in Agentic LLMs: Source Localization and Counterfactual Dependence Testing

cs.AI cs.CL ·2026-10-18 ·Junhao Liu, Tianxiao Li, Yongxian Wu, Ziheng Duan, Ren Li +2 more
publishedbenchmarkhot direction similarity 0.59
Abstract · 12 pages. Accepted at the NeurIPS 2026 Workshop on Agentic AI for Biological Discovery (AgenticLS)

Agentic LLMs increasingly support scientific prediction by grounding decisions in external evidence. In biology, they promise accurate, interpretable predictions for important problems by integrating complex experimental and computational evidence. However, serialized tool results can contain hidden label shortcuts, such as dataset identifiers or template artifacts, that create apparent success without biological reasoning. To address this risk, we introduce a two-stage audit. Stage 1, Per-Tool TF-IDF Decomposition (PT2D), localizes label-predictive patterns to individual tool results while avoiding signal dilution in the concatenated tool trace. Stage 2, Token-Class Redaction, counterfactually tests whether the frozen LLM depends on the localized shortcut. We apply this audit to TCR-pMHC binding, where tool augmentation substantially outperforms a no-evidence baseline. At face value, this suggests that the LLM has learned to use scientific evidence. The audit overturns this interpretation: PT2D localizes the strongest signal to identifiers in one tool result, and redacting them reduces performance to chance. These findings show how hidden label shortcuts can masquerade as scientific reasoning or discovery, motivating source-level audits before benchmark gains are trusted.

0.38

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

cs.AI ·2026-10-02 ·Jungkyu Park, Dhruva Biswas, Joseph Cappadona, Cerise Tang, Ken G. Zeng +20 more
similarity 0.59
Abstract

Scarcity of labeled data limits development of deep learning biomarkers in oncology. We develop a two-stage AI model predicting pathological complete response (pCR) to neoadjuvant therapy in breast cancer. The first stage learns the transcriptome from histopathology using 8,742 patients across 32 cancer types, corroborated by pathologist review and spatial agreement with measured expression. This simplifies the second stage to predicting pCR from inferred expression and clinical variables. Developed using 1,080 patients (five cohorts) and evaluated in 1,412 patients (nine cohorts), the model achieves a pooled AUROC of 0.79 (95% CI, 0.73-0.85), discriminating responders within molecular subtypes. It outperforms histopathological biomarkers, remaining stable across intratumoral sampling and with minimal biopsy tissue. Ablations show transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays' gene selection constraints. These results indicate that biologically informed compression may generalize to data-sparse applications in precision oncology.

0.06